#FLAURA2: Early ctDNA clearance didn’t identify who could forgo chemotherapy—PFS favored osimertinib + chemo regardless of week 1–2 clearance. Similar clearance rates, different ou

Elvina Almuradova· @Dr_ElvinaA · X·2026-10-24 15:00· 22 小时前评分70

正文 · 原文

#FLAURA2: Early ctDNA clearance didn’t identify who could forgo chemotherapy—PFS favored osimertinib + chemo regardless of week 1–2 clearance. Similar clearance rates, different outcomes. Exploratory, but clinically relevant! #ESMO26 @Larvol @myESMO @OncoAlert

10 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2719RO按 Rapid oral 1: NSCLC, metastatic 对上

FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)

https://esmocongress.esmo.org

LBA73按 Rapid oral 1: NSCLC, metastatic 对上

PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line

https://esmocongress.esmo.org

来源：Elvina Almuradova · x.com